Maze Therapeutics Announces Positive Phase 1 Trial Results for MZE782, Paving the Way for Phase 2 Trials in PKU and CKD by 2026
Maze Therapeutics Inc. announced positive Phase 1 trial results for MZE782, an oral small molecule targeting SLC6A19. The trial showed an excellent safety profile and significant pharmacodynamic effects, including a 42-fold increase in urinary phenylalanine excretion. No serious adverse events were reported. The company plans to start Phase 2 trials in 2026 to further assess MZE782's efficacy in treating phenylketonuria (PKU) and chronic kidney disease (CKD).
Maze Therapeutics Inc. has announced positive results from their Phase 1 clinical trial of MZE782, an oral small molecule targeting the solute transporter SLC6A19. The study, conducted with healthy volunteers, demonstrated an excellent safety profile and significant pharmacodynamic effects, including a 42-fold increase in urinary phenylalanine excretion. This suggests potential therapeutic benefits for patients with phenylketonuria (PKU) and chronic kidney disease (CKD). No serious adverse events were observed. Maze plans to initiate Phase 2 trials in 2026 to further investigate MZE782’s efficacy in reducing plasma phenylalanine levels in PKU and proteinuria in CKD. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527268-en) on September 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
